Ex-Galapagos medical chief heads to uniQure; Martin Mackay lines up Rallybio successor

Walid Abi-Saab

→ Former Galapagos exec Walid Abi-Saab has found a change in scenery, joining gene therapy biotech uniQure as CMO. He left Shire in 2017 to become medical chief at Galapagos, whose partnership with Gilead on filgotinib fell apart and is undergoing a rebuild with CEO Paul Stoffels. Abi-Saab announced his retirement at Galapagos in December alongside CBO André Hoekema; CFO and COO Bart Filius followed them out the door in early May. With Abi-Saab’s appointment, Ricardo Dolmetsch’s job title changes from R&D chief to president and CSO at uniQure, which released Phase I/II data for its Huntington’s gene therapy AMT-130 that flummoxed many observers. Stifel’s Paul Matteis labeled the data drop “very confusing” as uniQure’s stock $QURE took a dive.

Martin Mackay


Click here to view original post